Skip to Main Content

Paper Details

ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Sci Transl Med
39
2019
IL17RD, KRAS, KRAS mutant cancers, Kirsten rat, Kirsten rat sarcoma (KRAS) mutant lung cancer, Kras, Kras mutant, Lung tumors, MAPK, MEK, Mitogen-activated protein kinase (MAPK) kinase, ZEB1, cancer, epithelial, epithelial and mesenchymal lung tumors, epithelial lung cancer, epithelial lung cancer cells, histone deacetylase, human, interleukin-17 receptor D, lung tumor, miR, mitogen-activated protein kinase, mocetinostat, patient, resistant cancer cells, small hairpin RNA, tumor, zinc, zinc finger E-box binding homeobox 1
Author NameAffiliation
Lixia DiaoUniversity of Texas MD Anderson Cancer Center
Christopher A BristowUniversity of Texas MD Anderson Cancer Center
Christopher A BristowInstitute for Applied Cancer Science, University of Texas MD Anderson Cancer Center
Christopher A BristowUniversity of Texas MD Anderson Cancer Center
Christopher A BristowInstitute for Applied Cancer Science, University of Texas MD Anderson Cancer Center
Timothy P HeffernanUniversity of Texas MD Anderson Cancer Center
Timothy P HeffernanInstitute for Applied Cancer Science, University of Texas MD Anderson Cancer Center
  • 1 - 7

Datasets

Release 1.2